drugset / Trial / NCT02820987

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock

NCT02820987

Phase 3 Completed 119 enrolled Centre Hospitalier Universitaire de Besancon
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates PK/PD of an extended-infusion protocol of meropenem, piperacillin-tazobactam and cefepime, in the early phase of septic shock.

Timeline

Start
2016-09-27
Primary completion
2018-10-04
Completion
2018-10-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Amoxicillin Other / unclassified 16 g Other
Comparator Cefepime Small molecule 6 g Other
Comparator Meropenem Small molecule 2 g Other